Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07111520 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by BioNTech SE.

Recruiting
Registry status
Phase 1
Development phase
420
Enrollment target
2
Study locations

NCT07111520 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 420 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (36% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07111520, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by BioNTech SE.

RECRUITING
Registry status
Phase 1
Development phase
420 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available).

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG BNT327
  • DRUG BNT326
  • DRUG SoC

Study Locations (2)

Virginia

  • NEXT Virginia - Fairfax

Other

  • Institute of Oncology, ARENSIA Exploratory Medicine - Chisinau

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2025-09-22
Est. Completion 2030-01
Phase Phase 1

Sponsor

BioNTech SE

53 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07111520

The ClinicalTrials.gov registry entry for NCT07111520 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (36% lower). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT07111520 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Virginia, Other.

Frequently Asked Questions

What is clinical trial NCT07111520 about?

NCT07111520 is a clinical study titled "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)". This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult pa...

What is the current status of trial NCT07111520?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 420 participants. The study started on 2025-09-22. Estimated completion is 2030-01.

What conditions does trial NCT07111520 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT07111520?

The interventions under investigation include: Pembrolizumab (DRUG), BNT327 (DRUG), BNT326 (DRUG), SoC (DRUG).

Who is sponsoring clinical trial NCT07111520?

This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07111520 being conducted?

This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.